To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Cholangiocarcinoma|Biliary Tract Cancer|HER2-negative Breast Cancer|Triple Negative Breast Cancer|Small-cell Lung Cancer|Bladder Cancer|Prostate Cancer|Thyroid Cancer|Gastric Cancer|Gallbladder Cancer
Interventions: DRUG: TT-00420|DRUG: Combination Product: Atezolizumab|DRUG: Combination Product: Nab-Paclitaxel
Sponsor: TransThera Sciences (Nanjing), Inc.